Pier G B, Pollack M
Channing Laboratory, Brigham and Women's Hospital, Boston, Massachusetts 02115.
Infect Immun. 1989 Feb;57(2):426-31. doi: 10.1128/iai.57.2.426-431.1989.
A high-molecular-weight, immunogenic form of the lipopolysaccharide O side chain of Pseudomonas aeruginosa Fisher immunotype 4 (type 4, International Antigenic Typing System 1, Lanyi O:6) was isolated and characterized. Analysis by nuclear magnetic resonance spectroscopy confirmed the structural similarity of this high-molecular-weight polysaccharide and the type 4 O side chain. The polysaccharide was immunogenic in rabbits and mice, eliciting opsonophagocytic killing antibodies. Immunization with the polysaccharide produced significant protection against homologous challenge in both burned and granulocytopenic mice. Naturally acquired opsonic killing antibodies to type 4 polysaccharide were present in sera from unimmunized normal adults at levels comparable to postimmunization levels achieved after immunization with other type-specific polysaccharides. The specificity of the naturally occurring antibodies for the O side chain was documented by immunoblot analysis and inhibition studies. Naturally occurring polysaccharide-specific antibodies were comparable in their protective activity against live challenge in neutropenic animals to immunization-induced murine antibodies with similar specificity. These data suggest that naturally occurring serum antibody to P. aeruginosa type 4 lipopolysaccharide O side chains in most adults is not distinguishable in quantity or quality from immunization-induced antibodies in mice; evaluation of type 4-specific vaccines in humans may be complicated by this finding.
分离并鉴定了铜绿假单胞菌费舍尔免疫型4(4型,国际抗原分型系统1,兰伊O:6)脂多糖O侧链的一种高分子量、具有免疫原性的形式。核磁共振光谱分析证实了这种高分子量多糖与4型O侧链在结构上的相似性。该多糖在兔和小鼠中具有免疫原性,可引发调理吞噬杀伤抗体。用该多糖免疫对烧伤和粒细胞减少的小鼠均产生了对同源攻击的显著保护作用。未免疫的正常成年人血清中存在针对4型多糖的天然获得性调理杀伤抗体,其水平与用其他型特异性多糖免疫后达到的免疫后水平相当。免疫印迹分析和抑制研究证明了天然存在的抗体对O侧链的特异性。天然存在的多糖特异性抗体在对中性粒细胞减少动物的活攻击的保护活性方面与具有相似特异性的免疫诱导鼠抗体相当。这些数据表明,大多数成年人中针对铜绿假单胞菌4型脂多糖O侧链的天然血清抗体在数量或质量上与小鼠中的免疫诱导抗体没有区别;这一发现可能会使人类4型特异性疫苗的评估变得复杂。